MA30432B1 - Procede de traitement de l'hemochromatose hereditaire - Google Patents

Procede de traitement de l'hemochromatose hereditaire

Info

Publication number
MA30432B1
MA30432B1 MA31420A MA31420A MA30432B1 MA 30432 B1 MA30432 B1 MA 30432B1 MA 31420 A MA31420 A MA 31420A MA 31420 A MA31420 A MA 31420A MA 30432 B1 MA30432 B1 MA 30432B1
Authority
MA
Morocco
Prior art keywords
hereditary hemochromatosis
treatment
treating hereditary
compound
formula
Prior art date
Application number
MA31420A
Other languages
English (en)
Inventor
Hanspeter Nick
Lisa Rojkjaer
Janet Ellen Bodner
Peter Wayne Marks
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38859061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30432(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30432B1 publication Critical patent/MA30432B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE L'UTILISATION DU COMPOSÉ DE FORMULE (I) DANS LE TRAITEMENT DE SURCHARGE EN FER ENTRAÎNÉE PAR L'HÉMOCHROMATOSE HÉRÉDITAIRE CHEZ UN PATIENT QUI NÉCESSITE UN TEL TRAITEMENT ET UNE TROUSSE COMMERCIALE COMPRENANT LE COMPOSÉ DE FORMULE (I) ACCOMPAGNÉ D'INSTRUCTIONS POUR LE TRAITEMENT DE SURCHARGE EN FER CHEZ DE PATIENTS ATTEINTS DE L'HÉMOCHROMATOSE HÉRÉDITAIRE.
MA31420A 2006-05-23 2008-11-26 Procede de traitement de l'hemochromatose hereditaire MA30432B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74797406P 2006-05-23 2006-05-23
US80304906P 2006-05-24 2006-05-24
US83565806P 2006-08-04 2006-08-04

Publications (1)

Publication Number Publication Date
MA30432B1 true MA30432B1 (fr) 2009-05-04

Family

ID=38859061

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31420A MA30432B1 (fr) 2006-05-23 2008-11-26 Procede de traitement de l'hemochromatose hereditaire

Country Status (21)

Country Link
US (2) US20110105575A1 (fr)
EP (2) EP2255805A1 (fr)
JP (1) JP2009538329A (fr)
KR (1) KR20080112407A (fr)
AU (1) AU2007269536B2 (fr)
BR (1) BRPI0712020A2 (fr)
CA (1) CA2650433A1 (fr)
CL (1) CL2007001456A1 (fr)
DK (1) DK2026801T3 (fr)
ES (1) ES2440806T3 (fr)
HR (1) HRP20140096T1 (fr)
IL (1) IL194659A0 (fr)
MA (1) MA30432B1 (fr)
MX (1) MX2008014837A (fr)
NO (1) NO20084999L (fr)
NZ (1) NZ572155A (fr)
PL (1) PL2026801T3 (fr)
PT (1) PT2026801E (fr)
TN (1) TNSN08479A1 (fr)
TW (1) TW200808745A (fr)
WO (1) WO2008005624A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10694962B2 (en) 2011-06-13 2020-06-30 Cedars-Sinai Medical Center Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
US10694961B2 (en) 2011-06-13 2020-06-30 Cedaris-Sinai Medical Center Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
WO2024011188A1 (fr) * 2022-07-07 2024-01-11 Protagonist Therapeutics, Inc. Polythérapie pour le traitement de maladies de surcharge en fer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533205B (en) 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2650433A1 (fr) 2008-01-10
EP2026801A2 (fr) 2009-02-25
ES2440806T3 (es) 2014-01-30
IL194659A0 (en) 2009-08-03
KR20080112407A (ko) 2008-12-24
AU2007269536B2 (en) 2011-06-30
US20110105575A1 (en) 2011-05-05
US20110294861A1 (en) 2011-12-01
TW200808745A (en) 2008-02-16
EP2026801B1 (fr) 2013-11-06
PT2026801E (pt) 2014-02-06
EP2255805A1 (fr) 2010-12-01
NZ572155A (en) 2011-11-25
HRP20140096T1 (hr) 2014-02-28
TNSN08479A1 (en) 2010-04-14
WO2008005624A2 (fr) 2008-01-10
JP2009538329A (ja) 2009-11-05
WO2008005624A3 (fr) 2008-03-13
CL2007001456A1 (es) 2008-05-16
DK2026801T3 (da) 2014-01-27
MX2008014837A (es) 2008-12-01
NO20084999L (no) 2008-12-23
AU2007269536A1 (en) 2008-01-10
BRPI0712020A2 (pt) 2011-12-27
PL2026801T3 (pl) 2014-04-30

Similar Documents

Publication Publication Date Title
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
ATE368031T1 (de) Neue gamma secretase inhibitoren
MA35085B1 (fr) Procede de traitement d'une nephropathie induite par les produits de contraste
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA32903B1 (fr) Inhibiteurs de proteine-kinases
TNSN00121A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
TNSN01048A1 (fr) Acides malonamiques et leurs derives, et compositions les contenant
GB0225475D0 (en) Therapeutic agents
MA30782B1 (fr) Amides substitues, procede de production et d'utilisation desdits amides
MA31683B1 (fr) Composes et procedes pour moduler fxr
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
TNSN05249A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
MA30260B1 (fr) Acides 4-phenyl-thiazole-5-carboxyliques et amides d'acide 4-phenyl-thiazole-5-carboxylique en tant qu'inhibiteurs de plk 1
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
MA28583B1 (fr) Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA29543B1 (fr) Procedes pour traiter un cancer pharmacoresistant
MA33190B1 (fr) Composes pour le traitement de troubles metaboliques
MA32506B1 (fr) Nouveaux composes
MA34547B1 (fr) Traitement d'association pour traiter une infection par le vhc